Marshall Wace
BCLI

Marshall Wace’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Marshall Wace’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,495
Closed -$139K – 2194
2023
Q2 		$139K Buy
+4,495
New +$186K ﹤0.01% 2291
2023
Q1 		– Sell
-2,505
Closed -$61.6K – 2656
2022
Q4 		$61.6K Buy
2,505
+1,637
+189% +$61.2K ﹤0.01% 2831
2022
Q3 		$58K Buy
+868
New +$43.5K ﹤0.01% 3231

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Marshall Wace's BCLI Position: Q3 2023 in Review

Marshall Wace sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2023, closing a stake of 4,495 shares — an estimated $139K sold.

Marshall Wace first reported a position in BCLI in Q3 2022 and held it in 3 quarters. The position peaked at $139K in Q2 2023. 53 funds tracked by Wall St. Rank hold BCLI as of Q3 2023.

  • Marshall Wace reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2023 after selling out during the quarter.
  • Marshall Wace sold 4,495 BRAINSTORM CELL THERAPUTC shares in Q3 2023, an estimated $139K.
  • Marshall Wace first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2022 and held it in 3 quarters.
  • Marshall Wace's BRAINSTORM CELL THERAPUTC position peaked at $139K in Q2 2023.
  • 53 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2023.

Based on Marshall Wace's 13F filing for Q3 2023, filed 14 Nov 2023.